Singapore: US-based material science company, Corning, launched a new line of microcarriers for large-scale vaccine and cell therapy manufacturing. The microcarriers simplify the scale-up of attachment-dependent cells by providing a premeasured, sterile, ready-to-use product for direct transfer into bioreactors. This single-step microcarrier solution replaces several steps traditionally required and allows researchers to minimize lab preparation time and enhance manufacturing results.

"This new offering streamlines large-scale manufacturing, providing researchers with a single-step solution to free up vital resources," said Mr Ken Ludwig, business manager, bioprocess and cell therapy, Corning Life Sciences. "The new product reflects Corning's ongoing initiative to provide customers with efficient and complete solutions-from small-scale process development to large-scale manufacturing."

The new microcarriers offer Corning's unique Synthemax II and Enhanced Attachment surface treatment options to maximize cell yield and viability, and are fully compatible with closed systems solutions packaging in customizable batch sizes starting at 10g.

The new microcarriers represent the next step in Corning's ongoing scale-up offerings, joining Corning CellSTACK culture chambers, Corning HYPERStack vessels, which is a full range of spinner flasks, and advanced cell-culture media solutions.